

MONDAY, 27TH OCTOBER

12.00 – 14.00 **Registration**

13.30 – 13.45 **Opening and Greetings:**
Debora Berti, Andrea Galli, Andrea Morandi, Michele Caraglia

13.45 – 14.30 **OPENING LECTURE**

Persistence and diversity: challenges in treating gastric cancer

Silvia Giordano

University of Turin, Italy

14.30 – 15.00 **Coffee Break, Poster Viewing & Networking**

SESSION I: Metabolic Pathways in Therapy Response and Resistance

Chairs: Chiara Riganti, Pasquale Zizza, Alessandra Fiore

15.00 – 15.30 **Determinants of therapy resistance in breast cancer**

Elisabetta Marangoni

Institut Curie, Paris, France

15.30 – 15.45 **Model systems to trace cancer treatment and emergence of residual disease**

Martin Jechlinger – SELECTED

European Molecular Biology Laboratory EMBL, Heidelberg, Germany

15.45 – 16.00 **Loss of mitochondrial ECHDC2 expression reduces oxidative damage of nuclear DNA and causes radiotherapy resistance**

Paola Francica – SELECTED

University of Bern, Switzerland

16.00 – 16.15 **Agilent workflow for cancer research and immunotherapy**

Emma Nora Di Capua

Agilent DGG

16.15 – 16.45 **Tumor heterogeneity, ferroptosis and metastasis**

Arthur Mercurio

University of Massachusetts, USA

MONDAY, 27TH OCTOBER

- 16.45 – 17.00** **Targeting the stearyl-CoA desaturase SCD1 uncovers a ferroptosis vulnerability in proteasome inhibitor-resistant multiple myeloma**
Ludovica Ganino – SELECTED
University “Magna Graecia” of Catanzaro, Italy
- 17.00 – 17.15** **Fluidic platforms: how to mimic the human environment**
Silvia Quaglio
IVTech
- 17.15 – 17.45** **Elevator pitch presentations:**
Glutamate–oxaloacetate transaminase 2 (GOT2)-dependent aspartate availability confers ferroptosis resistance to disseminating prostate cancer cells
Sara Roccabianca
University of Florence, Italy
- BCMA-binding peptides: a dual approach for real-time monitoring and targeting tumor B cells**
Elisabetta Pingitore
University “Magna Graecia” of Catanzaro, Italy
- Predicting therapy resistance using targeted base editor screening**
Nicole Cona
University of Trento, Italy
- NAMPT inhibition impairs mTOR-dependent regulation of translation in melanoma**
Alberto Maria Todesco
University of Piemonte Orientale, Italy
- The cGAS/STING pathway mediates sensitivity and resistance to PARP inhibitors in Ewing sarcoma with an impact on the modulation of macrophage-related immune response**
Marianna Carrabotta
The Rizzoli Orthopaedic Institute IRCCS, Bologna, Italy

MONDAY, 27TH OCTOBER

miR-223-mediated metabolic alterations promote ferroptosis resistance and chemoresistance in laryngeal cancer

Michela Falco

University of Campania "L. Vanvitelli", Naples, Italy

Decoding the genetic landscape of laryngeal cancer

Federica Melisi

Biogem, Ariano Irpino, Italy

Exploiting metabolic vulnerabilities to prevent the onset of cisplatin resistance in ovarian carcinoma

Elena Capellini

Mario Negri Pharmacological Research Institute IRCCS, Milan, Italy

17.45 – 19.30 Welcome Cocktail & Poster Session

TUESDAY, 28TH OCTOBER

SESSION II: Chronic Diseases: Mechanisms of Therapy Response and Resistance

Chairs: Francesca Zazzeroni, Raffaele Addeo

9.00 – 9.30 **How to handle resistance to treatment in nephrotic syndrome**

Elena Lazzeri

University of Florence, Italy

9.30 – 10.00 **Linear ubiquitination as a resistance mechanism in metabolic syndrome**

Nieves Peltzer

University of Stuttgart, Germany

10.00 – 10.15 **MAP15k controls intracellular lipid uptake and protects mammalian liver from steatotic disease**

Mario Chiariello – SELECTED

The National Research Council CNR, Siena, Italy

TUESDAY, 28TH OCTOBER

10.15 – 10.45 Elevator pitch presentations:

The L370F ER α mutation confers resistance to CDK4/CDK6 inhibitors in a pre-clinical model

Filippo Acconcia

University of Roma Tre, Italy

Dual targeting of Hedgehog and DNA damage response pathways to suppress melanoma growth

Luisa Maresca

Institute for Cancer Research and Prevention ISPRO, Florence, Italy

Mapping genetic dependencies of drug-resistant cancer cells for the rational design of combinatorial treatments

Nevenka Radic

Human Technopole, Milan, Italy

TrkB-based signature identifies high-risk cutaneous squamous cell carcinoma and TrkB blockade reprograms tumor and stromal cells toward suppressive phenotypes

Valeria Bartolucci

The Istituto Dermatologico dell'Immacolata IDI IRCCS, Rome, Italy

The SGLT2 inhibitor Canagliflozin promotes colorectal cancer cell death via metabolic impairment

Isabella Donisi

University of Campania "L. Vanvitelli", Naples, Italy

ERK5 inhibition increases the expression and nuclear localization of EGFR in hepatocellular carcinoma, generating new targeting opportunities

Alessio Menconi

University of Siena, Italy

Identification of a novel biomarker for targeted therapy in gastric cancer treatment

Pellegrino Mazzone

Biogem, Ariano Irpino, Italy

TUESDAY, 28TH OCTOBER

Differentially expressed microRNAs in in vitro and in vivo glaucoma models:
unveiling molecular pathways and candidate therapeutic targets

Chiara Compagnoni

University of L'Aquila, Italy

10.45 – 11.15 Coffee Break, Poster Viewing & Networking

SESSION III: Unconventional Targets and Emerging Therapeutic Strategies

Chairs: Icro Meattini, Silvia Zappavigna, Joanna Kopecka

11.15 – 11.45 How to overcome cell death resistance in diffuse large B cell lymphoma

Alessandro Annibaldi

Center for Molecular Medicine Cologne CMMC, University of Cologne, Germany

11.45 – 12.15 Rare mutations in cancer: the case of NTRK1-3 fusions and Larotrectinib

Michele Caraglia

University of Campania "L. Vanvitelli", Naples, Italy

12.15 – 12.30 EV purification & characterization: where precision meets potential

Maira Bacchiaga

Izon Science - Schaefer SEE Srl

12.30 – 12.45 Beyond expression - functional quantification of immune checkpoints with QF-Pro®

Olatz Larrañaga

Cytosens

12.45 – 13.00 WEE1 inhibition as a therapeutic strategy for overcoming secondary resistance to targeted therapies in colorectal cancer

Sabrina Arena – SELECTED

University of Turin, Italy

13.00 – 13.15 Targeting epigenetic co-dependencies to overcome endocrine therapy resistance in breast cancer

Giovanni Nassa – SELECTED

University of Salerno, Italy

TUESDAY, 28TH OCTOBER

13:15 – 14.45 **Poster Session & Light Lunch**

SESSION IV: Molecular Predictors of Therapy Response

Chairs: Massimo Donadelli, Maria Teresa Di Martino

14.45 – 15.15 **Monitoring treatment response in patients with metastatic cancer using epigenetic biomarkers**

Matteo Benelli

University of Florence, Italy

15.15 – 15.45 **Tracking colorectal cancer evolution in liquid biopsy**

Federica Di Nicolantonio

University of Turin, Italy

15.45 – 16.00 **Timing cancer genomics driver events around therapy**

Alice Antonello – SELECTED

University of Trieste, Italy

16.00 – 16.15 **ctDNA and cfMeDip as a tool to predict response in metastatic melanoma under anti-PD1 + anti-CTLA4 treatments**

Francesco Caraglia – SELECTED

University of Campania “L. Vanvitelli”, Naples, Italy

16.15 – 16.30 **The next evolution of droplet digital PCR**

Mattia Criscuoli

Bio-Rad Laboratories

16.30 – 17.00 **Coffee Break , Poster Viewing & Networking**

SESSION V: Decoding Heterogeneity in Therapeutic Response

Chairs: Enrico De Smaele, Caterina Mancarella

17.00 – 17.30 **Multimomics correlation with clinical response in immuno-oncology**

Michele Ceccarelli

Miller School of Medicine, Miami, USA

TUESDAY, 28TH OCTOBER

- 17.30 – 18.00** **Spatio-temporal T cell tracking for personalized TCR-T designs in childhood cancer**
Alexandra Avgustinova
Institute for Research in Biomedicine IRB, Barcelona, Spain
- 18.00 – 18.15** **Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells**
Federica Danzi – SELECTED
University of Verona, Italy
- 18.15 – 18.45** **Transcriptional footprints of cancer dependency shock as a computational tool for early anti-cancer drug discovery**
Francesco Iorio
Human Technopole, Milan, Italy
- 18.45 – 19.15** **AICC General Assembly**
- 20.00** **SOCIAL EVENT: “Terrazze Michelangelo”**

WEDNESDAY, 27TH OCTOBER

SESSION VI: The Tumor Microenvironment in Therapy Resistance

Chairs: Elisa Giannoni, Katia Scotlandi, Simone Di Franco,

- 9.00 – 9.30** **Extracellular nutrients drive metabolic stress resistance and support metastatic organotropism in prostate cancer: when tumor cells go hunting the most favorable environment**
Paola Chiarugi
University of Florence, Italy
- 9.30 – 10.00** **Targeting inflammation in the tumour microenvironment by blocking cytokine signalling: implications in response to immunotherapy**
Maria M. Caffarel
Ikerbasque, Biogipuzkoa Health Research Institute, San Sebastian, Spain

WEDNESDAY, 29TH OCTOBER

- 10.00 – 10.15** **Heterogeneous gene expression programs define the tumor ecosystem of laryngeal squamous cell carcinoma: insights from single-cell transcriptomics**
Marianna Scrima – SELECTED
Biogen, Ariano Irpino, Italy
- 10.15 – 10.30** **The miR11/MALAT-1 ceRNA circuit controls chemoresistance in lung cancer by rewiring the metabolism of cancer cells and cancer-associated immune cells**
Niloufar Jafari – SELECTED
University of Turin, Italy
- 10.30 – 10.45** **CAIX inhibition by SLC-0111 induces immunogenic cell death and reverses FLOT resistance in gastric cancer**
Elena Andreucci – SELECTED
University of Florence, Italy
- 10.45 – 11.00** **Impact of p-cresyl sulfate on colorectal cancer progression under uremic conditions**
Rossella Di Paola – SELECTED
University of Campania “L. Vanvitelli”, Naples, Italy
- 11.00 – 11.30** **Coffee Break & Networking**
- Chairs: *Andrea Morandi, Nicla Lorito, Michele Caraglia*
- 11.30 – 12.15** **CLOSING LECTURE**
Targeting the tumour microenvironment (and sarcomas)
Clare Isacke
The Institute of Cancer Research ICR, London, UK
- 12.15 – 12.45** **Awards Ceremony and Closing Remarks**